An Appeal from JSA Haryana

 An Appeal from JSA Haryana

Breast cancer, by the government’s estimate, is the leading cause of
cancer in women in India. The Indian Council of Medical Research
(ICMR) in a report this month said that 100.5 per 1,00,000 women were
being diagnosed with breast cancer. From the approximately 1,82,000
cases of breast cancer at present, the report has projected cases to
rise to 250,000 by 2030. Luminal A, the most serious type of invasive
breast cancer and comprises the bulk of breast cancer cases.. The
drugs necessary to treat this condition Ribociclib, Palbociclib and
Abemaciclib are too expensive and unavailable at an affordable price
because these are patented drugs.

In this situation, JSA Haryana   demands that

1.     Introduce Ribociclib, Palbociclib and Abemaciclib as part of the free treatment program under the National Cancer Control Program

2.     Central Government should invoke Compulsory a licence Under
Section 84, 92 and 100 of the Indian Patent Act to facilitate free and
affordable access to these three cancer medicines through generic
production.
     JSA Haryana request different mass organisations to consider adopting a resolution to this effect and give wide publicity to the resolution.
Dr R.S.Dahiya
JSA state core member